Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders

A method of treating a CTGF signaling-associated ocular disorder in a subject in need thereof, comprising:

• administering to the subject a composition comprising:
• an effective amount of an antagonist of CI-M6P/IGF2R, or a pharmaceutically acceptable salt or prodrug thereof;
• and
• a pharmaceutically acceptable carrier;
• wherein the CTGF signaling-associated ocular disorder is treated thereby.

A method of treating glaucoma in a subject, comprising:

• administering to the subject a composition comprising:
• an effective amount of an antagonist of CI-M6P/IGF2R, or a pharmaceutically acceptable salt or prodrug thereof;
• and
• a pharmaceutically acceptable carrier;
• wherein the glaucoma is treated thereby.

A method of treating glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, or proliferative vitreoretinopathy in a subject, comprising:

• administering to the subject a composition comprising:
• an effective amount of an antagonist of CI-M6P/IGF2R or a pharmaceutically acceptable salt or prodrug thereof;
• and
• a pharmaceutically acceptable carrier;
• wherein the glaucomatous retinopathy, optic neuropathy, macular degeneration, diabetic retinopathy, choroidal neovascularization, or proliferative vitreoretinopathy is treated thereby.